logo-loader

e-Therapeutics passes significant milestone as it establishes safe maximum dose for lead drug

Last updated: 02:45 18 Dec 2014 EST, First published: 03:45 18 Dec 2014 EST

communications_tower_350_5357c9dde6dbd
AT&T, together with Verizon Communications Inc. (NYSE:VZ), grapples with stiff competition from T-Mobile US Inc. (NYSE:PCS) and Sprint Corp. (NYSE:S). The company's churn rate, which measures the number of customers who leave, increased to 1.07 percent in the first quarter from 1.04 percent last year.

e-Therapeutics (LON:ETX) said it has established the safe maximum dose for its potential cancer treatment ETS2101.

This is a significant milestone in that it allows researchers to take the drug into the next stage of development.

Phase Ib studies will concentrate on specific solid tumours, the first two being hepatocellular carcinoma, the most common type of liver cancer, and pancreatic cancer, a terminal form of the disease.

Steve Self, the company’s development director, said: "Having established the maximum tolerated dose, we can now investigate further the positive characteristics of ETS2101 as a potential cancer treatment for patients.” 


e-Therapeutics present at the Proactive One2One Investor Forum - October 26th

Ali Mortazavi, CEO of e-Therapeutics PLC (AIM:ETX, OTCQX:ETXPF), addressed the challenges of traditional drug discovery, emphasising its high risk, extensive timeline, and considerable cost at the Proactive One2One Investor Forum. Underlining the inefficiencies of this model, Mortazavi posed...

on 11/01/2023